

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-28 (canceled)

Claim 29 (currently amended) A compound ~~according to claim 1, wherein the compound which is 2-[6-{[2-(3-hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or a prodrug, N-oxide, pharmaceutically acceptable salt, quaternary amine, or metal complex thereof.~~

Claim 30 (canceled)

Claim 31 (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and ~~as active ingredient a therapeutically effective amount of a compound as described in any one of claims 1 to~~ claim 29.

Claim 32 (canceled)

Claim 33 (canceled)

Claim 34 (new) A method for treating or preventing a viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the compound of claim 29.

Claim 35 (new) A method for treating or preventing a respiratory syncytial viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the compound of claim 29.

Claim 36 (new) A method for treating or preventing a viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the composition of claim 31.

Claim 37 (new) A method for treating or preventing a respiratory syncytial viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the composition of claim 31.

Claim 38 (new) A pharmaceutical composition made by mixing the compound of Claim 29 and a pharmaceutically acceptable carrier.

Claim 39 (new) A process for making a pharmaceutical composition comprising mixing the compound of Claim 29 and a pharmaceutically acceptable carrier.

Claim 40 (new) The pharmaceutical composition of claim 31, further comprising an antiviral agent.

Claim 41 (new) The pharmaceutical composition of claim 31, further comprising an antiviral agent selected from the group consisting of interferon-beta and tumor necrosis factor-alpha.

Claim 42 (new) A method of treating a warm-blooded animal infected by a virus, or being at risk of infection by a virus, comprising administering to the warm-blooded animal an anti-virally effective amount of the compound of claim 29.

Claim 43 (new) A method of treating a warm-blooded animal infected by a respiratory syncytial virus, or being at risk of infection by a respiratory syncytial virus, comprising administering to the warm-blooded animal an anti-virally effective amount of the compound of claim 29.

Claim 44 (new) A method for treating or preventing a respiratory syncytial viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the compound of claim 29 and an antiviral agent.

Claim 45 (new) The method of claim 44, wherein the antiviral agent is selected from the group consisting of interferon-beta and tumor necrosis factor-alpha.

Claim 46 (new) A method of treating a warm-blooded animal infected by a respiratory syncytial virus, or being at risk of infection by a respiratory syncytial virus, comprising administering to the warm-blooded animal an anti-virally effective amount of the compound of claim 29 and an antiviral agent.

Claim 47 (new) The method of claim 46, wherein the antiviral agent is selected from the group consisting of interferon-beta and tumor necrosis factor-alpha.

Claim 48 (new) A compound which is 2-[6-{[2-(3-hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol and pharmaceutically acceptable salts thereof.

Claim 49 (new) A pharmaceutical composition comprising the compound of Claim 48 and a pharmaceutically acceptable carrier.

Claim 50 (new) A method for treating or preventing a viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the compound of claim 48.

Claim 51 (new) A method for treating or preventing a respiratory syncytial viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the compound of claim 48.

Claim 52 (new) A method for treating or preventing a viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the composition of claim 49.

Claim 53 (new) A method for treating or preventing a respiratory syncytial viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the composition of claim 49.

Claim 54 (new) A pharmaceutical composition made by mixing the compound of Claim 48 and a pharmaceutically acceptable carrier.

Claim 55 (new) A process for making a pharmaceutical composition comprising mixing the compound of Claim 48 and a pharmaceutically acceptable carrier.

Claim 56 (new) The pharmaceutical composition of claim 49, further comprising an antiviral agent.

Claim 57 (new) The pharmaceutical composition of claim 49, further comprising an antiviral agent selected from the group consisting of interferon-beta and tumor necrosis factor-alpha.

Claim 58 (new) A method of treating a warm-blooded animal infected by a virus, or being at risk of infection by a virus, comprising administering to the warm-blooded animal an anti-virally effective amount of the compound of claim 48.

Claim 59 (new) A method of treating a warm-blooded animal infected by a respiratory syncytial virus, or being at risk of infection by a respiratory syncytial virus, comprising administering to the warm-blooded animal an anti-virally effective amount of the compound of claim 48.

Claim 60 (new) A method for treating or preventing a respiratory syncytial viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the compound of claim 48 and an antiviral agent.

Claim 61 (new) The method of claim 60, wherein the antiviral agent is selected from the group consisting of interferon-beta and tumor necrosis factor-alpha.

Claim 62 (new) A method of treating a warm-blooded animal infected by a respiratory syncytial virus, or being at risk of infection by a respiratory syncytial virus, comprising administering to the warm-blooded animal an anti-virally effective amount of the compound of claim 48 and an antiviral agent.

Claim 63 (new) The method of claim 62, wherein the antiviral agent is selected from the group consisting of interferon-beta and tumor necrosis factor-alpha.

Claim 64 (new) A compound which is 2-[6-{[2-(3-hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol.

Claim 65 (new) A pharmaceutical composition comprising the compound of Claim 64 and a pharmaceutically acceptable carrier.

Claim 66 (new) A method for treating or preventing a viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the compound of claim 64.

Claim 67 (new) A method for treating or preventing a respiratory syncytial viral infection comprising administering to a subject in need thereof an anti-virally effective amount of the compound of claim 64.